Over the past decade, an increasing number of immunotherapies aiming to improve the ability of the immune system to effectively eradicate tumor cells have been developed. Among them, targeting effector T cell subsets of the immune system with bispecific antibodies, called T Cell Engagers (TCEs), represents an attractive strategy. TCEs are designed to specifically direct cytotoxic T cells towards tumor cells, thereby inducing a strong activation leading to the lysis of tumor cells. New strategies for targeting specific T-cell subsets are currently being explored. In this study, we investigated the activity of different TCEs on both conventional alpha beta (αβ) T cells and unconventional gamma delta (γδ) T cells. We generated TCE molecules based on camelid single-domain antibodies (VHHs) that target the tumor-associated antigen CEACAM5 (CEA), together with particular T-cell receptor chains (TCRs) or a CD3 domain. The in vitro biological activity of the TCEs against the colon carcinoma cell line LS174T was measured using fresh and cultured human Vγ9Vδ2 and αβ T cells. We showed that Vγ9Vδ2 T cells display stronger antitumor activity in vitro than αβ T cells when activated with a CD3xCEA TCE. Furthermore, restricting T cell activation to Vγ9Vδ2 T cells limits the production of pro-tumor factors and pro-inflammatory cytokines, which are often associated with toxicity in patients. Taken together, these results suggest that Vγ9Vδ2γδ T cell-specific TCEs may represent safe, novel, specific, and effective molecules for improving antitumor immunotherapies.